Latest News and Press Releases

Zug, Switzerland, Nov. 3, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...

TACTT3 Phase 3 trial protocol amended based on analysis of TACTT2 trial outcomes TACTT3 enrollment to be expanded with top-line results expected in early 2018 Conference call scheduled for...

Zug, Switzerland, October 10, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Presentation of safety data from KeyzilenTM program and symposium on tinnitus pharmacotherapy set for September 18 and 19 ZUG, Switzerland, September 13, 2016 -- Auris Medical Holding AG...

ZUG, Switzerland, September 9, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

TACTT2 trial with KeyzilenTM for acute inner ear tinnitus did not meet efficacy endpoints Top-line results from TACTT3 trial with KeyzilenTM expected in the fourth quarter of 2016 AM-111 Phase...

TACTT2 trial did not meet its co-primary efficacy endpoints Top-line results from the Phase 3 TACTT3 trial expected in the fourth quarter of 2016 Second quarter 2016 financial results and...

Zug, Switzerland, August 16, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Zug, Switzerland, July 19, 2016 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...

Fast Track designation highlights potential of KeyzilenTM to address unmet medical need Top-line results from Phase 3 TACTT2 trial expected next month Zug, Switzerland, July 18, 2016 - Auris...